With the emergence of the Decentralized Clinical Trial (DCT) model over the last decade and the continued trend toward remote and virtual patient capabilities for participants in clinical studies, it is important to recognize that not all capabilities associated with DCTs provide perceived benefits in equal measure.
Assessing why some capabilities are more beneficial than others to the industry and trial participants is imperative for successful implementation of DCT capabilities and for maximizing returns provided by the DCT paradigm shift.
Read this article to learn how to enable and empower study teams to implement a customized combination of DCT capabilities that assures the efficiency and success of each individual trial and maximizes convenience and accessibility.
Download the article below
